The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.